A Short History
The modern research era has two very different chapters, separated by a long, painful silence.
1950s–60s — the first wave. Researchers including Humphry Osmond, Abram Hoffer, Walter Pahnke, and Timothy Leary explored whether a chemically occasioned mystical experience was, in any meaningful sense, the same as a spontaneous one. Pahnke’s 1962 “Good Friday Experiment” at Marsh Chapel remains one of the most striking studies in the literature; a long-term follow-up found participants still describing what happened, decades later, as genuinely mystical and personally meaningful — not a drug effect that faded with the high, but something that had actually changed them [1,2]. Trials using LSD to treat alcoholism around the same time found real benefit from a single high-dose session — strongest in the weeks after dosing, though not reliably holding at the longest follow-ups researchers checked [3].
1970–2006 — dormancy. Psychedelics were criminalized in 1970. With rare exceptions (Rick Strassman’s DMT research among them), clinical study of these medicines stopped for over three decades [4].
2006–present — the renaissance. Roland Griffiths and colleagues at Johns Hopkins reopened the field with a study whose title says almost everything worth knowing about where it was headed: “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning” [5]. Most volunteers — healthy, psychedelic-naïve people given a single high dose — rated the experience as among the most personally meaningful of their lives, on par for many with the birth of a child. Benefits were still measurable fourteen months later [6]. Just as important: the paper helped establish a real way to measure something as slippery as a mystical experience — what became, through further validation work, the Mystical Experience Questionnaire (MEQ) — the methodological step that made everything that followed possible [7].
Evidence by Condition
Worth knowing honestly rather than treating psychedelics as a cure-all — the evidence has grown unevenly by condition.
Depression — the strongest evidence base. Landmark trials at Johns Hopkins and NYU found rapid, lasting relief in people with life-threatening cancer and depression; roughly 80% of the Hopkins participants showed meaningful improvement six months later [8,9]. A 2020 Hopkins trial found the same rapid antidepressant effect in major depressive disorder more broadly [10]. For treatment-resistant depression specifically, a large pharmaceutical trial program (COMPASS Pathways’ COMP360) has now reported hitting its primary endpoint in two separate Phase 3 trials, with fast-acting relief sustained through six weeks and no meaningful rise in suicidal thinking across trial arms [11]. Real-world data shows meaningful, if smaller, benefit — and some people needed more than one session before the shift held, which tells us dosing schedules are still an open question.
Anxiety — strong evidence, especially at the end of life, tracking closely with the depression findings above [8,9].
PTSD — promising, earlier-stage. Safety and feasibility data, including a 2026 pilot in veterans with severe, treatment-resistant PTSD, are encouraging — real signal, but the large, confirmatory trials that would establish real efficacy aren’t complete yet [12]. This is worth being especially careful about, since PTSD is where many people drawn to this work — veterans especially — are hoping for answers the evidence doesn’t fully support yet.
Parkinson’s disease — early but notable. A single, first-of-its-kind UCSF pilot study found sustained benefit in mood through three months, with improvements in movement and cognitive symptoms also seen at the one-month mark [13]. There’s a real, still-unproven hypothesis that the medicine may touch the underlying disease biology, not just mood riding on top of it. Larger trials are underway.
Dementia and Alzheimer’s — a frontier, not a treatment. The animal research is compelling; the human evidence right now is essentially one closely watched case report [14]. Anything said here should be read as an emerging direction, not an established finding.
The Key Finding: Depth of Experience and Surrender Predict Outcome
The single most important finding in this research isn’t really about the drug at all. Across study after study, the strongest predictor of lasting benefit isn’t the dose, or even how intense the experience felt — it’s the depth of the mystical-type experience, and how much a person resists versus allows the dissolving of their usual sense of self. One well-known study of treatment-resistant depression found that this quality of experience, together with how much a person dreaded that dissolving, explained more than half the variance in who got dramatically better and who didn’t — a striking amount for psychiatric research [15].
That’s not only a fact about psilocybin. It’s the same law that governs the ego, the fear-based thought system, and the process of letting go described on Beyond Personal History. The molecule doesn’t do the healing. Surrender does. It’s worth being honest that not every study has found this pattern — at least one long-term follow-up of a well-controlled trial didn’t find mystical experience predicting outcome the same way most of the field’s research does — so this is a strong, well-replicated pattern, not an iron law [16]. Some healing clearly comes through other doors too: insight, emotional breakthrough, and the simple, human safety of being well held by someone trustworthy.
Difficult Passages Aren’t Failure
Survey data shows that people who move through a hard passage during a session, rather than fighting it, tend to come out the other side with more life satisfaction and meaning, not less [17]. This is the same instruction whether someone is sitting across a desk in an ordinary counseling session or moving through something difficult in a guided journey: don’t resist what’s arising, move toward it, let it be known. What waits on the other side of that surrender is very often something that feels sacred.
A Few Additional Research Nuances
Worth folding in, since they sharpen — without changing — the picture above:
Mystical experience isn’t the only psychological predictor worth naming. Some researchers have found that “emotional breakthrough” — a felt sense of confronting and moving through avoided emotional material during the session, measured with what’s called the Emotional Breakthrough Inventory — tracks with outcome at least as strongly as the depth of the mystical-type experience itself, sometimes more so [18].
The evidence doesn’t look like a simple placebo effect. In at least one trial, how much a participant expected to benefit beforehand predicted their response to a comparison antidepressant, but not their response to psilocybin [19].
A head-to-head trial against a standard antidepressant (escitalopram) is informative, not a clean win either way. The two treatments didn’t differ significantly on the primary measure used in that trial, but psilocybin came out ahead on most secondary measures (not adjusted for multiple comparisons) — and a follow-up brain-imaging study on the same participants found the antidepressant group’s brain response to emotional expressions dulled, while psilocybin’s wasn’t [20,21].
More isn’t automatically better. The dose-response picture is more nuanced than “more is simply better.” In one large trial, a moderate dose produced no more benefit than a near-placebo dose, while adverse events — including suicidal-ideation events — were more common at both the moderate and full dose than at the near-placebo dose. Separately, earlier dose-ranging research found that as dose climbed toward the doses typically used in trials, so did acute fear and anxiety during the session — real reasons not to chase a bigger dose in search of a better outcome [22,23].
Adverse effects are real, if uncommon, and worth naming honestly. Persistent perceptual changes after use (sometimes called HPPD) are a recognized, if rare, risk [24]. Younger people may also carry somewhat elevated risk for negative psychological responses generally, though this finding is recent and not yet widely replicated — one more reason careful screening matters [25].
A practical note for anyone already on an SSRI: SSRIs are believed to blunt the subjective intensity of a psychedelic experience for many people, even when they don’t rule out its use altogether — worth knowing ahead of time so a muted experience isn’t mistaken for the medicine “not working” or the person “doing it wrong” [26,27].
